Literature DB >> 9161789

Bone marrow transplantation for inherited diseases.

A S O'Marcaigh1, M J Cowan.   

Abstract

Allogeneic bone marrow transplantation has been used successfully for the treatment of a variety of inherited diseases. The goal of transplantation in this setting is to provide a sufficient degree of sustained marrow engraftment to allow longterm amelioration of the inherited disease phenotype. Many factors influence the likelihood of achieving this goal, including donor availability, conditioning regimen, marrow processing, and the nature and extent of progression of the disease. For many inherited diseases early diagnosis is imperative because the outcome of transplantation is more favorable when performed prior to the development of significant organ damage from the disease, its complications, or treatment. Although the results of bone marrow transplantation are good for some inherited diseases and are improving for others, significant problems remain such as donor availability, conditioning regimen toxicity, graft failure, and graft-versus-host disease. This review describes some of the unique features of bone marrow transplantation for inherited diseases and discusses recent advances in this area.

Entities:  

Mesh:

Year:  1997        PMID: 9161789

Source DB:  PubMed          Journal:  Curr Opin Oncol        ISSN: 1040-8746            Impact factor:   3.645


  8 in total

1.  Osteoblast-specific gene expression after transplantation of marrow cells: implications for skeletal gene therapy.

Authors:  Z Hou; Q Nguyen; B Frenkel; S K Nilsson; M Milne; A J van Wijnen; J L Stein; P Quesenberry; J B Lian; G S Stein
Journal:  Proc Natl Acad Sci U S A       Date:  1999-06-22       Impact factor: 11.205

2.  Mesenchymal Stem Cells in Cardiology.

Authors:  Ian A White; Cristina Sanina; Wayne Balkan; Joshua M Hare
Journal:  Methods Mol Biol       Date:  2016

3.  Bone marrow transplantation does not ameliorate the neurologic symptoms in mice deficient in hypoxanthine guanine phosphoribosyl transferase (HPRT).

Authors:  B E Wojcik; H A Jinnah; C E Muller-Sieburg; T Friedmann
Journal:  Metab Brain Dis       Date:  1999-03       Impact factor: 3.584

Review 4.  Gene therapy for lysosomal storage diseases (LSDs) in large animal models.

Authors:  Mark Haskins
Journal:  ILAR J       Date:  2009

Review 5.  Animal models for mucopolysaccharidosis disorders and their clinical relevance.

Authors:  Mark E Haskins
Journal:  Acta Paediatr       Date:  2007-04       Impact factor: 2.299

6.  Isolated allogeneic bone marrow-derived mesenchymal cells engraft and stimulate growth in children with osteogenesis imperfecta: Implications for cell therapy of bone.

Authors:  Edwin M Horwitz; Patricia L Gordon; Winston K K Koo; Jeffrey C Marx; Michael D Neel; Rene Y McNall; Linda Muul; Ted Hofmann
Journal:  Proc Natl Acad Sci U S A       Date:  2002-06-25       Impact factor: 11.205

7.  Umbilical cord blood transplantation in severe T-cell immunodeficiency disorders: two-year experience.

Authors:  A P Knutsen; D A Wall
Journal:  J Clin Immunol       Date:  2000-11       Impact factor: 8.542

Review 8.  Use of gonadotropin-releasing hormone (GnRH) agonist trigger in fertility preservation for patients with inherited genetic disorders.

Authors:  Jamie Merkison; Carrie Malcom; Alan Decherney
Journal:  Front Endocrinol (Lausanne)       Date:  2022-09-06       Impact factor: 6.055

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.